Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmacopeia has announced that it is implementing the next step in its ongoing effort to focus its resources on the company's clinical and later-stage discovery programs.
Subscribe to our email newsletter
This effort includes an immediate workforce reduction of approximately 15% through attrition and termination of positions as well as a decrease in other expenses through improved operational efficiencies and increased financial discipline. The company’s annual operating expenditures are expected to decrease by at least $10 million in 2009.
In the second quarter of 2008, Pharmacopeia expects to record a charge of approximately $800,000 in connection with the severance provided to employees directly affected by the reduction in staffing.
Joseph Mollica, chairman of the board of directors and CEO of Pharmacopeia, said: “We believe that, with the recent announcement of our positive Phase IIa results for PS433540 (DARA), it is the appropriate time to continue executing our plan to allocate a greater share of our resources towards our later-stage programs.”